IL6 and severe acute respiratory syndrome: As in SARS-CoV infections (Jiang et al., 2005), the systemic levels of pro-inflammatory cytokine IL-6 was particularly associated with the severity of SARS-CoV-2 pathology (Zhu et al., 2020) and anti-IL-6 antibody therapy seems promising in early studies exploring its utility in the therapy SARS-CoV-2 (Xu et al., 2020).